Cargando…
The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT
BACKGROUND: Invasive fungal infections (IFI) are difficult to diagnose, especially in critically ill patients. As the mannose receptor (MR) is shed from macrophage cell surfaces after exposure to fungi, we investigate whether its soluble serum form (sMR) can serve as a biomarker of IFI. METHODS: Thi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679534/ https://www.ncbi.nlm.nih.gov/pubmed/31375142 http://dx.doi.org/10.1186/s13054-019-2549-8 |
_version_ | 1783441357491142656 |
---|---|
author | De Vlieger, Greet Vanhorebeek, Ilse Wouters, Pieter J. Derese, Inge Casaer, Michael P. Debaveye, Yves Hermans, Greet Meersseman, Philippe Møller, Holger J. Van den Berghe, Greet Ingels, Catherine |
author_facet | De Vlieger, Greet Vanhorebeek, Ilse Wouters, Pieter J. Derese, Inge Casaer, Michael P. Debaveye, Yves Hermans, Greet Meersseman, Philippe Møller, Holger J. Van den Berghe, Greet Ingels, Catherine |
author_sort | De Vlieger, Greet |
collection | PubMed |
description | BACKGROUND: Invasive fungal infections (IFI) are difficult to diagnose, especially in critically ill patients. As the mannose receptor (MR) is shed from macrophage cell surfaces after exposure to fungi, we investigate whether its soluble serum form (sMR) can serve as a biomarker of IFI. METHODS: This is a secondary analysis of the multicentre randomised controlled trial (EPaNIC, n = 4640) that investigated the impact of initiating supplemental parenteral nutrition (PN) early during critical illness (Early-PN) as compared to withholding it in the first week of intensive care (Late-PN). Serum sMR concentrations were measured in three matched patient groups (proven/probable IFI, n = 82; bacterial infection, n = 80; non-infectious inflammation, n = 77) on the day of antimicrobial initiation or matched intensive care unit day and the five preceding days, as well as in matched healthy controls (n = 59). Independent determinants of sMR concentration were identified via multivariable linear regression. Serum sMR time profiles were analysed with repeated-measures ANOVA. Predictive properties were assessed via area under the receiver operating curve (aROC). RESULTS: Serum sMR was higher in IFI patients than in all other groups (all p < 0.02), aROC to differentiate IFI from no IFI being 0.65 (p < 0.001). The ability of serum sMR to discriminate infectious from non-infectious inflammation was better with an aROC of 0.68 (p < 0.001). The sMR concentrations were already elevated up to 5 days before antimicrobial initiation and remained stable over time. Multivariable linear regression analysis showed that an infection or an IFI, higher severity of illness and sepsis upon admission were associated with higher sMR levels; urgent admission and Late-PN were independently associated with lower sMR concentrations. CONCLUSION: Serum sMR concentrations were higher in critically ill patients with IFI than in those with a bacterial infection or with non-infectious inflammation. However, test properties were insufficient for diagnostic purposes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13054-019-2549-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6679534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66795342019-08-06 The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT De Vlieger, Greet Vanhorebeek, Ilse Wouters, Pieter J. Derese, Inge Casaer, Michael P. Debaveye, Yves Hermans, Greet Meersseman, Philippe Møller, Holger J. Van den Berghe, Greet Ingels, Catherine Crit Care Research BACKGROUND: Invasive fungal infections (IFI) are difficult to diagnose, especially in critically ill patients. As the mannose receptor (MR) is shed from macrophage cell surfaces after exposure to fungi, we investigate whether its soluble serum form (sMR) can serve as a biomarker of IFI. METHODS: This is a secondary analysis of the multicentre randomised controlled trial (EPaNIC, n = 4640) that investigated the impact of initiating supplemental parenteral nutrition (PN) early during critical illness (Early-PN) as compared to withholding it in the first week of intensive care (Late-PN). Serum sMR concentrations were measured in three matched patient groups (proven/probable IFI, n = 82; bacterial infection, n = 80; non-infectious inflammation, n = 77) on the day of antimicrobial initiation or matched intensive care unit day and the five preceding days, as well as in matched healthy controls (n = 59). Independent determinants of sMR concentration were identified via multivariable linear regression. Serum sMR time profiles were analysed with repeated-measures ANOVA. Predictive properties were assessed via area under the receiver operating curve (aROC). RESULTS: Serum sMR was higher in IFI patients than in all other groups (all p < 0.02), aROC to differentiate IFI from no IFI being 0.65 (p < 0.001). The ability of serum sMR to discriminate infectious from non-infectious inflammation was better with an aROC of 0.68 (p < 0.001). The sMR concentrations were already elevated up to 5 days before antimicrobial initiation and remained stable over time. Multivariable linear regression analysis showed that an infection or an IFI, higher severity of illness and sepsis upon admission were associated with higher sMR levels; urgent admission and Late-PN were independently associated with lower sMR concentrations. CONCLUSION: Serum sMR concentrations were higher in critically ill patients with IFI than in those with a bacterial infection or with non-infectious inflammation. However, test properties were insufficient for diagnostic purposes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13054-019-2549-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-02 /pmc/articles/PMC6679534/ /pubmed/31375142 http://dx.doi.org/10.1186/s13054-019-2549-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research De Vlieger, Greet Vanhorebeek, Ilse Wouters, Pieter J. Derese, Inge Casaer, Michael P. Debaveye, Yves Hermans, Greet Meersseman, Philippe Møller, Holger J. Van den Berghe, Greet Ingels, Catherine The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT |
title | The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT |
title_full | The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT |
title_fullStr | The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT |
title_full_unstemmed | The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT |
title_short | The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT |
title_sort | soluble mannose receptor (smr/scd206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the epanic rct |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679534/ https://www.ncbi.nlm.nih.gov/pubmed/31375142 http://dx.doi.org/10.1186/s13054-019-2549-8 |
work_keys_str_mv | AT devliegergreet thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT vanhorebeekilse thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT wouterspieterj thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT dereseinge thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT casaermichaelp thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT debaveyeyves thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT hermansgreet thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT meerssemanphilippe thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT møllerholgerj thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT vandenberghegreet thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT ingelscatherine thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT devliegergreet solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT vanhorebeekilse solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT wouterspieterj solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT dereseinge solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT casaermichaelp solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT debaveyeyves solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT hermansgreet solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT meerssemanphilippe solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT møllerholgerj solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT vandenberghegreet solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct AT ingelscatherine solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct |